Seeding Collaborations for Translational Research to Discover and Develop New Therapies for Diseases and Conditions within NIDDKs Mission (Revisions) (R01) | Apply Online

Opportunity Summary:

This NIH grant opportunity (PAR-14-006) was a discretionary R01 revision program run by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to help existing NIDDK-funded investigators quickly form and support new collaborations aimed at translational therapy development. Rather than funding brand-new standalone R01 projects, the mechanism focused on administrative or competitive revisions to active NIDDK R01 awards, allowing a currently funded research team to expand its approved Specific Aims in a targeted way. The underlying idea was to use a relatively small amount of additional money to bring in complementary expertise, tools, or partners so that promising basic discoveries could be pushed further down the early development pipeline toward credible therapeutic possibilities for diseases and conditions within NIDDKs mission areas (including diabetes, digestive diseases, nutrition-related conditions, and kidney and urologic diseases).

The scientific scope emphasized practical, early-stage translational work that bridges discovery biology and preclinical development. Supported activities included identifying and prioritizing therapeutic targets, doing early pharmacological validation to show that modulating a target has a meaningful effect, generating and evaluating "pre-therapeutic" leads, and then moving those leads through lead optimization steps. The FOA also allowed limited preclinical development work, meaning the added aims could extend beyond proof-of-concept and into small, focused packages of preclinical studies that make a potential therapy more development-ready. In plain terms, the program was meant to help a lab or team that already has strong NIDDK-funded science take the next steps that often require a different skill set (for example, medicinal chemistry, pharmacology, assay development, translational models, or other specialized capabilities) and to do so through deliberate, collaboration-driven project expansion.

Collaboration was not treated as optional window dressing; it was the point of the announcement. The revision structure was intended to make it easier to add new partners and approaches to an existing project, such as pairing a disease biology group with a drug discovery group, a pharmacology team, a screening facility, an industry collaborator, or another academic lab with key enabling technology. By supporting additional aims attached to an active award, NIDDK was effectively encouraging researchers to build translational "hand-offs" earlier, so the work could move from a mechanistic finding to something that looks more like a tractable therapeutic program.

From an administrative standpoint, the opportunity was categorized as a grant (Funding Instrument Type: Grant) under the NIH/NIDDK extramural research umbrella (CFDA 93.847). It did not require cost sharing or matching. The award ceiling listed was $75,000, signaling that this was intended as a modest, catalytic supplement rather than a large-scale development budget. The announcement was posted on November 21, 2013, and it remained open until the closing date of January 7, 2017, with an archive date of February 7, 2017, meaning it is no longer active but remains part of the public record for reference.

Eligibility was broad and reflected standard NIH inclusivity for organizational applicants. Eligible applicants included public and private institutions of higher education, nonprofit organizations (including both 501(c)(3) and non-501(c)(3) entities), for-profit organizations (including small businesses and other for-profits), and a wide range of government entities (state, county, city or township, special district governments, independent school districts, and public housing authorities/Indian housing authorities). The eligibility language also explicitly included many mission-driven and capacity-building institution types such as HBCUs, Hispanic-serving institutions, Tribally Controlled Colleges and Universities, Alaska Native and Native Hawaiian Serving Institutions, and AANAPISI institutions, along with tribal governments (federally recognized and other than federally recognized). Importantly, foreign organizations and foreign institutions were eligible to apply, foreign components of U.S. organizations were allowed, and foreign components as defined by the NIH Grants Policy Statement were permitted, reinforcing that NIDDK was open to international expertise when it strengthened the translational collaboration and advanced the therapeutic development goals.

Operationally, applicants were directed to the full FOA text on the NIH grants site (PAR-14-006) for the detailed instructions and requirements associated with submitting an R01 revision, and the NIH Office of Extramural Research webmaster contacts were provided for technical access issues. Overall, the program can be read as a targeted NIDDK effort to accelerate the conversion of strong, ongoing basic and mechanistic research into early therapeutic development packages by funding small but strategic expansions to existing R01 projects, with collaboration and translational milestones (target validation, lead generation, optimization, and limited preclinical development) at the center of what it was trying to achieve.

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Food and Nutrition Health

Next opportunity: Continuum of Prevention, Care and Treatment of HIV/AIDS in Most at Risk Poupulations in Cameroon CHAMP

Previous opportunity: Advances in Patient Safety through Simulation Research (R18)

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for PAR 14 006

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (PAR 14 006) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "PAR 14 006", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.